12 research outputs found

    Consensus guidelines for the use and interpretation of angiogenesis assays

    Get PDF
    The formation of new blood vessels, or angiogenesis, is a complex process that plays important roles in growth and development, tissue and organ regeneration, as well as numerous pathological conditions. Angiogenesis undergoes multiple discrete steps that can be individually evaluated and quantified by a large number of bioassays. These independent assessments hold advantages but also have limitations. This article describes in vivo, ex vivo, and in vitro bioassays that are available for the evaluation of angiogenesis and highlights critical aspects that are relevant for their execution and proper interpretation. As such, this collaborative work is the first edition of consensus guidelines on angiogenesis bioassays to serve for current and future reference

    Histidine-Rich Glycoprotein Modulates the Anti-Angiogenic Effects of Vasculostatin

    No full text
    Brain angiogenesis inhibitor 1 (BAI1) is a transmembrane protein expressed on glial cells within the brain. Its expression is dramatically down-regulated in many glioblastomas, consistent with its functional ability to inhibit angiogenesis and tumor growth in vivo. We have shown that the soluble anti-angiogenic domain of BAI1 (termed Vstat120) requires CD36, a cell surface glycoprotein expressed on microvascular endothelial cells (MVECs), for it to elicit an anti-angiogenic response. We now report that Vstat120 binding to CD36 on MVECs activates a caspase-mediated pro-apoptotic pathway, and this effect is abrogated by histidine-rich glycoprotein (HRGP). HRGP is a circulating glycoprotein previously shown to function as a CD36 decoy to promote angiogenesis in the presence of thrombospondin-1 or −2. Data here show that Vstat120 specifically binds HRGP. Under favorable MVEC growth conditions this interaction allows chemotactic-directed migration as well as endothelial tube formation to persist in in vitro cellular systems, and increased tumor growth in vivo as demonstrated in both subcutaneous and orthotopic brain tumor models, concomitant with an increase in tumor vascularity. Finally, we show that HRGP expression is increased in human brain cancers, with the protein heavily localized to the basement membrane of the tumors. These data help define a novel angiogenic axis that could be exploited for the treatment of human cancers and other diseases where excess angiogenesis occurs

    Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy.

    Get PDF
    Transcriptome profiles derived from the site of human disease have led to the identification of genes that contribute to pathogenesis, yet the complex mixture of cell types in these lesions has been an obstacle for defining specific mechanisms. Leprosy provides an outstanding model to study host defense and pathogenesis in a human infectious disease, given its clinical spectrum, which interrelates with the host immunologic and pathologic responses. Here, we investigated gene expression profiles derived from skin lesions for each clinical subtype of leprosy, analyzing gene coexpression modules by cell-type deconvolution. In lesions from tuberculoid leprosy patients, those with the self-limited form of the disease, dendritic cells were linked with MMP12 as part of a tissue remodeling network that contributes to granuloma formation. In lesions from lepromatous leprosy patients, those with disseminated disease, macrophages were linked with a gene network that programs phagocytosis. In erythema nodosum leprosum, neutrophil and endothelial cell gene networks were identified as part of the vasculitis that results in tissue injury. The present integrated computational approach provides a systems approach toward identifying cell-defined functional networks that contribute to host defense and immunopathology at the site of human infectious disease

    Cell-type deconvolution with immune pathways identifies gene networks of host defense and immunopathology in leprosy

    No full text
    Submitted by Sandra Infurna ([email protected]) on 2017-02-21T11:07:45Z No. of bitstreams: 1 euzenir_sarno_etal_IOC_2016.pdf: 1438335 bytes, checksum: aa97b092804532f27f2c242364567135 (MD5)Approved for entry into archive by Sandra Infurna ([email protected]) on 2017-02-21T11:30:39Z (GMT) No. of bitstreams: 1 euzenir_sarno_etal_IOC_2016.pdf: 1438335 bytes, checksum: aa97b092804532f27f2c242364567135 (MD5)Made available in DSpace on 2017-02-21T11:30:39Z (GMT). No. of bitstreams: 1 euzenir_sarno_etal_IOC_2016.pdf: 1438335 bytes, checksum: aa97b092804532f27f2c242364567135 (MD5) Previous issue date: 2016David Geffen School of Medicine at UCLA. Department of Molecular. Cell, and Developmental Biology. California, USA.David Geffen School of Medicine at UCLA. Division of Dermatology. California, USA.David Geffen School of Medicine at UCLA. Division of Dermatology. California, USA.David Geffen School of Medicine at UCLA. Division of Dermatology. California, USA.David Geffen School of Medicine at UCLA. Division of Dermatology. California, USA.David Geffen School of Medicine at UCLA. Department of Molecular. Cell, and Developmental Biology. California, USA.David Geffen School of Medicine at UCLA. Department of Molecular. Cell, and Developmental Biology. California, USA.University College London. Division of Infection and Immunity. London, United Kingdom.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Hanseníase. Rio de Janeiro, RJ. Brasil.University of Southern California School of Medicine. Department of Dermatology. Los Angeles, CA, USA.University of Southern California School of Medicine. Department of Dermatology. Los Angeles, CA, USA.David Geffen School of Medicine at UCLA. Department of Molecular. Cell, and Developmental Biology. California, USA.University of Michigan School of Medicine. Department of Dermatology. Ann Arbor, Michigan, USA.Leiden University Medical Center. Department of Infectious Diseases. Leiden, Netherlands.Leiden University Medical Center. Department of Infectious Diseases. Leiden, Netherlands.Harvard School of Public Health. Boston, Massachusetts, USA.David Geffen School of Medicine at UCLA. Department of Molecular. Cell, and Developmental Biology. California, USA.David Geffen School of Medicine at UCLA. Division of Dermatology. California, USA / UCLA. Department of Microbiology, Immunology and Molecular Genetics. Los Angeles, California, USATranscriptome profiles derived from the site of human disease have led to the identification of genes that contribute to pathogenesis, yet the complex mixture of cell types in these lesions has been an obstacle for defining specific mechanisms. Leprosy provides an outstanding model to study host defense and pathogenesis in a human infectious disease, given its clinical spectrum, which interrelates with the host immunologic and pathologic responses. Here, we investigated gene expression profiles derived from skin lesions for each clinical subtype of leprosy, analyzing gene coexpression modules by cell-type deconvolution. In lesions from tuberculoid leprosy patients, those with the self-limited form of the disease, dendritic cells were linked with MMP12 as part of a tissue remodeling network that contributes to granuloma formation. In lesions from lepromatous leprosy patients, those with disseminated disease, macrophages were linked with a gene network that programs phagocytosis. In erythema nodosum leprosum, neutrophil and endothelial cell gene networks were identified as part of the vasculitis that results in tissue injury. The present integrated computational approach provides a systems approach toward identifying cell-defined functional networks that contribute to host defense and immunopathology at the site of human infectious disease
    corecore